DIA421.51-2.72 -0.64%
SPX5,886.55+42.36 0.72%
IXIC19,010.09+301.74 1.61%

Ginkgo Bioworks Holdings First Quarter 2025 Earnings: Beats Expectations

Simply Wall St·05/08/2025 11:24:41
Listen to the news

Ginkgo Bioworks Holdings (NYSE:DNA) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$48.3m (up 27% from 1Q 2024).
  • Net loss: US$91.0m (loss narrowed by 45% from 1Q 2024).
  • US$1.68 loss per share (improved from US$3.31 loss in 1Q 2024).
Our free stock report includes 2 warning signs investors should be aware of before investing in Ginkgo Bioworks Holdings. Read for free now.
earnings-and-revenue-growth
NYSE:DNA Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ginkgo Bioworks Holdings Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 5.1%.

Looking ahead, revenue is expected to decline by 3.6% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the US are expected to grow by 4.1%.

Performance of the American Chemicals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Ginkgo Bioworks Holdings that you should be aware of before investing here.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.